cfap161 Antibody

What is CFAP161 and where is it expressed?

CFAP161 is an evolutionary conserved 303 amino acid protein that lacks domains of known biochemical function. It is primarily expressed in cells containing motile cilia, with high expression levels correlating with the presence of motile cilia and co-expression of the transcription factor FOXJ1 . In mice, CFAP161 expression is detected in the ciliated ventral layer of the embryonic node, ependymal cells of the brain, epithelial cells of the eustachian tube, respiratory epithelium, ciliated lung epithelial cells, oviduct cells with motile cilia, and in testis . Interestingly, CFAP161 is also detected in some cells lacking motile cilia, such as retinal cells and cells with primary (immotile) cilia, including hair cells in the inner ear and kidney collecting duct cells .

How is CFAP161 regulated in ciliated cells?

CFAP161 expression depends on the transcription factor FOXJ1, which is a master regulator of motile ciliogenesis. This dependency has been confirmed in both mouse and Xenopus models. In FOXJ1 null mutant mouse fetuses, CFAP161 protein is not detected in tissues. Similarly, in Xenopus foxj1-crispants, there is global downregulation of cfap161 expression, particularly noticeable in multiciliated cells of the epidermis. Unilateral foxj1 gain-of-function in Xenopus strongly induces cfap161 transcription, further confirming this regulatory relationship .

What antibodies are available for CFAP161 detection?

For mouse CFAP161 detection, researchers have generated both monoclonal and polyclonal antibodies:

Both antibodies have been validated by detecting Flag-tagged CFAP161 overexpressed in CHO cells as well as endogenous CFAP161 in testis lysates. They also detect CFAP161 expression during ciliogenesis in air-liquid interface cultures of mouse tracheal epithelial cells .

How does CFAP161 localize within ciliary structures?

Immunofluorescence studies using both α-pI and α-pII antibodies have shown that CFAP161 co-localizes with acetylated-α-tubulin in motile cilia, confirming it as a component of ciliary structures. Notably, CFAP161 and acetylated-α-tubulin staining do not overlap in the distal part of cilia, indicating that CFAP161 is excluded from the cilium tip. This pattern is most clearly observed in nasal respiratory epithelium sections . This exclusion from the cilium tip is consistent with the localization of its Chlamydomonas orthologue in outer microtubule doublets and likely reflects that outer doublets terminate earlier than the central inner pair .

In Xenopus, direct detection of endogenous CFAP161 has been challenging, but heterologously expressed murine CFAP161 tagged with N-terminal EGFP (GFP-CFAP161) partially co-localizes with Cetn4-RFP, which marks basal bodies of epidermal multiciliated cells. Interestingly, most GFP-CFAP161 signal appears in anterior juxtaposition underneath each basal body, suggesting rootlet association .

What experimental approaches can resolve contradictory findings about CFAP161 function?

Contradictory findings exist regarding CFAP161 function, particularly from zebrafish studies where morpholino-mediated knockdown resulted in different phenotypes across studies. One study reported loss of outer dynein arms, reduced pronephric cilia beating frequency, and left-right asymmetry defects, while another reported only curved body axis and hydrocephalus .

To resolve such contradictions, researchers should consider:

• Using multiple genetic disruption methods (CRISPR-Cas9, conditional knockouts)

• Analyzing phenotypes across different developmental stages

• Employing quantitative functional assays for cilia (video microscopy for beating patterns and frequency)

• Performing detailed ultrastructural analysis via electron microscopy

• Conducting cross-species validation studies

• Examining potential genetic compensation mechanisms

Importantly, RNA-seq analysis of CFAP161 mutant mice revealed dysregulation of genes related to microtubules, cilia, microtubule motor activity, and inner dyneins, suggesting potential compensatory mechanisms that might buffer CFAP161 mutation effects .

What protein interactions might explain CFAP161's molecular function?

Mass spectrometry analysis of CFAP161 complexes immunoprecipitated from wild-type testis lysates using the polyclonal α-pII antibody identified potential interaction partners. One significant interaction partner is KIAA0556 (also known as KATNIP), a basal body protein that stabilizes cytoplasmic microtubules in human cells and regulates ciliary A-tubule number in C. elegans . When mutated, KIAA0556 causes Joubert syndrome in humans. Yeast-two-hybrid analysis validated a robust interaction between CFAP161 and KIAA0556, supporting a potential function of CFAP161 in microtubule organization or function .

This interaction data suggests experimental approaches involving:

• Co-immunoprecipitation studies

• Proximity labeling techniques (BioID, APEX)

• Super-resolution microscopy to examine co-localization

• Functional assays examining cytoskeletal properties in CFAP161-deficient cells

What are the optimal procedures for CFAP161 antibody validation?

Proper validation of CFAP161 antibodies is critical for reliable research outcomes. Based on approaches used in the literature, a comprehensive validation protocol should include:

• Western blot analysis:

  • Testing against tagged recombinant protein (e.g., Flag-tagged CFAP161)

  • Detection of endogenous protein in appropriate tissues (e.g., testis lysates)

  • Confirmation of specificity using knockout/knockdown tissues or cells

• Immunohistochemistry validation:

  • Comparison of staining patterns with known expression domains from in situ hybridization

  • Absence of signal in knockout/knockdown tissues

  • Co-localization with established ciliary markers (e.g., acetylated-α-tubulin, IFT88)

• Functional validation:

  • Ability to immunoprecipitate CFAP161 complexes that can be verified by mass spectrometry

  • Consistent staining patterns across different fixation and permeabilization protocols

As demonstrated in the literature, both monoclonal and polyclonal antibodies against CFAP161 show consistent detection of the protein, with expression patterns matching mRNA distribution .

How can immunofluorescence protocols be optimized for CFAP161 detection in ciliary structures?

For optimal detection of CFAP161 in ciliary structures, researchers should consider the following protocol optimizations:

What approaches can overcome difficulties in detecting endogenous CFAP161 in certain species?

Detection of endogenous CFAP161 has proven challenging in some species, such as Xenopus. Researchers have encountered difficulties where overexpressed tagged CFAP161 shows non-specific localization throughout the cell . To overcome these challenges:

• Antibody development strategies:

  • Generate species-specific antibodies targeting highly conserved epitopes

  • Consider using multiple antibodies targeting different regions of the protein

  • Employ monoclonal antibodies for higher specificity

• Alternative detection methods:

  • CRISPR knock-in of small epitope tags (e.g., FLAG, HA) at the endogenous locus

  • Proximity labeling approaches (BioID, APEX) to map CFAP161 interactions and localization

  • Use of fluorescent protein tags expressed at physiological levels

• Expression system optimization:

  • Titrate expression levels to avoid overexpression artifacts

  • Use endogenous promoters rather than strong exogenous promoters

  • Consider inducible expression systems

• Signal enhancement techniques:

  • Tyramide signal amplification for immunofluorescence

  • RNAscope for high-sensitivity mRNA detection as a proxy for protein expression

How should researchers interpret the lack of phenotype in CFAP161 knockout models?

One of the most surprising findings about CFAP161 is that despite its evolutionary conservation and specific expression in ciliated cells, disruption of the Cfap161 gene in both Xenopus and mouse did not lead to expected motile cilia-related phenotypes . When interpreting this apparent contradiction, researchers should consider:

A thorough interpretation requires combining multiple approaches to determine whether CFAP161 truly lacks essential function or whether its role is masked by compensatory mechanisms.

What analyses can reveal subtle phenotypes in CFAP161-deficient models?

Standard phenotypic analyses might miss subtle defects in CFAP161-deficient models. To detect potential subtle phenotypes, researchers should consider:

• High-resolution ciliary beat pattern analysis:

  • High-speed videomicroscopy (>200 frames per second)

  • Quantitative analysis of beat frequency, amplitude, and waveform

  • Measurement under various conditions (temperature changes, viscosity challenges)

• Ultrastructural analyses:

  • Transmission electron microscopy of ciliary cross-sections

  • Cryo-electron tomography to visualize molecular details

  • Immunogold labeling to track protein localization at ultrastructural level

• Stress response testing:

  • Subject models to environmental stressors that might reveal conditional phenotypes

  • Analyze recovery after ciliary damage

• Multi-omics approach:

  • Transcriptomics to identify compensatory gene expression changes

  • Proteomics to detect alterations in protein composition of cilia

  • Metabolomics to identify changes in cellular metabolism

• Aging studies:

  • Phenotypes might only become apparent with age

  • Progressive ciliary dysfunction might develop over time

These approaches can help determine whether CFAP161 deficiency causes subtle functional changes that might be physiologically relevant but not immediately apparent in standard phenotypic analyses.

How might CFAP161 research contribute to understanding ciliopathies?

Although direct links between CFAP161 mutations and human ciliopathies have not been established, several lines of evidence suggest potential relevance:

• Human CFAP161 (c15orf26) is located on chromosome 15q in the linkage region of Kartagener syndrome, suggesting a potential involvement of Cfap161 mutations in this subtype of Primary Ciliary Dyskinesia (PCD) .

• CFAP161 interacts with KIAA0556 (KATNIP), which when mutated causes Joubert syndrome in humans . This interaction suggests CFAP161 might be part of pathways relevant to ciliopathies.

• The outer dynein arm defects reported in some zebrafish knockdown studies are reminiscent of defects seen in certain forms of PCD.

Future research directions should include:

• Genetic screening of ciliopathy patients for CFAP161 variants

• Analysis of CFAP161 function in human cellular models

• Investigation of CFAP161 in the context of known ciliopathy-associated protein networks

• Examination of potential genetic interactions between CFAP161 and established ciliopathy genes

What new technologies might advance CFAP161 research?

Emerging technologies that could advance our understanding of CFAP161 include:

• Cryo-electron tomography:

  • Can reveal precise molecular localization within ciliary structures

  • May identify structural changes in cilia from CFAP161-deficient models

• Live-cell super-resolution imaging:

  • Would allow tracking of CFAP161 dynamics during ciliogenesis

  • Could reveal transient interactions not captured by fixed-cell imaging

• Proximity labeling proteomics (BioID, APEX):

  • Can identify proteins in close proximity to CFAP161 in living cells

  • Might reveal dynamic interactions during ciliary assembly and function

• Single-cell transcriptomics:

  • Could identify cell-type specific responses to CFAP161 deficiency

  • Might reveal compensatory mechanisms in specific ciliated cell populations

• CRISPR screening:

  • Systematic identification of genetic interactions with CFAP161

  • Discovery of synthetic lethal or suppressor interactions

These technologies could provide novel insights into CFAP161 function and potentially resolve the contradiction between its evolutionary conservation and apparent dispensability.